{"id":"asp1585","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Decreased libido"},{"rate":null,"effect":"Erectile dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ASP1585 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide more complete suppression of androgen receptor signaling in hormone-sensitive cancers.","oneSentence":"ASP1585 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:41.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer (CRPC)"},{"name":"Hormone-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT01903213","phase":"","title":"Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-19","conditions":"Chronic Renal Failure","enrollment":123},{"nctId":"NCT02805348","phase":"","title":"Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-01","conditions":"Chronic Kidney Disease","enrollment":144},{"nctId":"NCT01901107","phase":"","title":"Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-01","conditions":"Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis","enrollment":1078},{"nctId":"NCT02753894","phase":"PHASE2","title":"Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-01","conditions":"Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia","enrollment":73},{"nctId":"NCT02531204","phase":"PHASE1","title":"A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-08","conditions":"Healthy, Urine Phosphorus Excretion","enrollment":60},{"nctId":"NCT01742611","phase":"PHASE3","title":"Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03","conditions":"Chronic Kidney Disease, Renal Insufficiency, Hyperphosphatemia","enrollment":105},{"nctId":"NCT01057407","phase":"PHASE3","title":"A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01","conditions":"Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency","enrollment":110},{"nctId":"NCT00892749","phase":"PHASE3","title":"Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency","enrollment":248},{"nctId":"NCT01017276","phase":"PHASE3","title":"A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-11","conditions":"Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency","enrollment":35},{"nctId":"NCT01742585","phase":"PHASE3","title":"A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10","conditions":"Chronic Kidney Disease, Renal Insufficiency, Hyperphosphatemia","enrollment":163},{"nctId":"NCT01124747","phase":"PHASE1","title":"A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-04","conditions":"Healthy, Pharmacokinetics of ASP1585","enrollment":12},{"nctId":"NCT00505037","phase":"PHASE2","title":"A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-10","conditions":"Hyperphosphatemia, Chronic Kidney Disease","enrollment":156},{"nctId":"NCT01115972","phase":"PHASE1","title":"A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-03","conditions":"Healthy, Pharmacokinetics of Valsartan","enrollment":24},{"nctId":"NCT01115985","phase":"PHASE1","title":"A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-03","conditions":"Healthy, Pharmacokinetics of Atorvastatin","enrollment":24},{"nctId":"NCT01115946","phase":"PHASE1","title":"A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-03","conditions":"Healthy, Pharmacokinetics of Enalapril","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ILY101","AMG223","Bixalomer","Kiklin (R)","LY101"],"phase":"phase_3","status":"active","brandName":"ASP1585","genericName":"ASP1585","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP1585 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}